Cerus Corporation Celebrates World Blood Donor Day 2023
June 14 2023 - 8:30AM
Business Wire
Cerus Corporation (Nasdaq: CERS) is proud to announce its
celebration of World Blood Donor Day 2023.
In 2005, the World Health Assembly designated June 14 as World
Blood Donor Day to recognize and thank blood donors across the
world for their important contributions to the global blood supply.
For 2023, the focus of this day is on those patients who rely on
blood products over their lifetime, and the donors who make this
possible, with the slogan “Give blood, give plasma, share life,
share often.”
“Over the last few years, it has been more evident than ever
before that our blood supply is fragile,” stated William ‘Obi’
Greenman, Cerus’ president and chief executive officer. “Those
individuals who choose to donate repeatedly are essential to the
availability of all blood products for transfusion. We are honored
to support – and be a part of – this community.”
Although blood centers everywhere are continuously recruiting
for new donors, the pool of available donors remains small and
geographically limited. According to the World Health Organization
(WHO), more than 118.5 million blood donations are collected
annually around the world, with 40% of these donations collected in
high-income countries, which contain only 16% of the global
population. A wide variety of patients regularly receive blood
transfusion, including cardiovascular surgery, transplant surgery,
massive trauma, cancer, obstetric, and childhood anemia
patients.1
“Blood products for transfusion are essential to a functional
healthcare system, yet they continue to be in short supply on a
regular basis across the globe. At Cerus, we are focused on
enabling both blood safety and availability through technology
innovation, including expansion of donor eligibility when
feasible,” Greenman continued. “Whether for daily transfusion
requirements or pandemic preparedness, the blood supply depends on
the generosity of donors every single day.”
In recognition of World Blood Donor Day, Cerus will host a blood
drive at company headquarters and encourages everyone to
participate in supporting blood product availability in their local
communities.
-
https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Headquartered in Concord, California, the company
develops and supplies vital technologies and pathogen-protected
blood components to blood centers, hospitals, and ultimately
patients who rely on safe blood. The INTERCEPT Blood System for
platelets and plasma is available globally and remains the only
pathogen reduction system with both CE mark and FDA approval for
these two blood components. The INTERCEPT red blood cell system is
under regulatory review in Europe, and in late-stage clinical
development in the US. Also in the US, the INTERCEPT Blood System
for Cryoprecipitation is approved for the production of Pathogen
Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to
as INTERCEPT Fibrinogen Complex), a therapeutic product for the
treatment and control of bleeding, including massive hemorrhage,
associated with fibrinogen deficiency. For more information about
Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230614161931/en/
Jessica Hanover – Vice President, Corporate Affairs Cerus
Corporation 925-288-6137
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Apr 2024 to May 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From May 2023 to May 2024